Medigene reports outcome of Annual General Meeting
Shareholders approve all resolutions with a high majority
New Supervisory Board elected for the period until 2019
Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the shareholders of the company approved all resolutions with large majorities during the Annual General Meeting yesterday.
At the Annual General Meeting 2016 of Medigene AG, 45.5% of the voting shares were represented. The approval rates of the proposed resolutions were between 93.2 and 99.9%.
Prof. Dr. Horst Domdey, Dr. Yita Lee and Antoinette Hiebeler-Hasner were elected as members of the new Supervisory Board with a term until 2019. Prof. Dr. Domdey will continue, as in the previous term, as the chairman of the Supervisory Board, Mrs Hiebeler-Hasner will represent the position of the financial expert of the Audit Committee.
Prof. Dr. Dolores Schendel, CEO and CSO of Medigene AG commented: "We are very pleased with the broad support of our shareholders. Their approval of our strategic proposals enables us to further develop the company in the innovative field of immunotherapies. On behalf of the Board I thank the shareholders of Medigene AG for their vote of confidence."
For more information please follow the link: http://www.medigene.com/media-investors/annual-general-meeting/2016
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com